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Nicole Dalessio, BSN, RN, CPN, Ashley Divincenzo, BSN, RN, CPN, Kendra Savage, BSN, RN, CPN and Samantha Steich, BSN, RN, CPN
Pediatric Unit 
Lehigh Valley Health Network, Allentown, Pa.
PURPOSE/LEARNING OBJECTIVES
Share pragmatic tactics designed to reduce the incidence of severe 
hyperbilirubinemia in the neonatal period.
BACKGROUND/EVIDENCE
•  Hyperbilirubinemia is a common cause of hospital admission in neonates.
•  Severe hyperbilirubinemia can lead to acute bilirubin encephalopathy
and kernicterus – a form of irreversible neurological damage.
•  American Association of Pediatrics (AAP) guidelines (2004) recommend:
	 n  Before discharge, every newborn should be assessed for the risk of 
developing severe hyperbilirubinemia. 
	 n  Protocols for assessing this risk should be in place.
•  Infants readmitted for hyperbilirubinemia should have a total serum
bilirubin (TSB) level of ≤ 14 mg/dL in order to discontinue phototherapy
and be considered for outpatient management (AAP, 2004).
•  At an academic, 1,200 bed Magnet® facility inpatient pediatric unit, no
standardized approach existed to assess and treat hyperbilirubinemia.
•  Pre-intervention data (Oct.–Dec., 2017):
	 n  Mean length of stay (LOS) for infants undergoing triple phototherapy 
was 27 hours




• June, 2017 – An organizational-level
interprofessional decision-making group
the 'Children’s Hospital Process and
Quality Improvement Council' (CH PQIC)
met to improve the clinical processes by
developing a care pathway for the infant
at risk of severe hyperbilirubinemia
• July, 2017 – Clinical pathway charter
developed and presented to the CH PQIC
CREATE
Workgroup activities August/September 2017:
• Performed a literature search
• Created a care algorithm
• Defined inclusion and
exclusion criteria
• Outlined metrics
• Identified tools needed for
pathway implementation
• Developed an electronic health
record (EHR) order set
• Met with clinical products staff
to approve use of light drapes
in patient care
• Educated Family Medicine
Hospitalists
IMPLEMENT
Workgroup activities October/November 2017:
• Developed a plan for data collection
• Nurse educators delivered an electronic
self-study and live pathway education to
RNs on the pediatric unit
• Updated and published the network policy
regarding care of inpatients with
hyperbilirubinemia
January 1, 2018:
• Activated the EHR hyperbilirubinemia
order set
• Pathway approved and
implemented on the pediatric unit
February, 2018 to present:
• Ongoing monitoring and data
collection of defined pathway metrics
RESULTS
OUTCOME MEASURES:
•  Decreased LOS in the neonate admitted with hyperbilirubinemia
•  Increased percent of infants with TSB <=14 on day discharge
LENGTH OF STAY INFANTS ADMITTED TO THE 
PEDIATRIC UNIT WITH HYPERBILIRUBINEMIA
TOTAL SERUM BILIRUBIN ≤14 ON DAY OF DISCHARGE 
INFANTS RECEIVING TRIPLE PHOTOTHERAPY
CHALLENGES/LESSONS LEARNED
•  Bilirubin light drapes:
	 n  Required collaboration with 
our network products 
department to attain and 
stock equipment
•  Pathway integration with Family Medicine and
interdisciplinary teams outside of the division was
challenging
	 n  Workgroup members met with Family Medicine 
representatives to brainstorm ways to improve 
pathway compliance
NEXT STEPS
•  Introduce and implement the neonatal hyperbilirubinemia 
pathway on the Mother/Baby and Neonatal Intensive 
Care units.
REFERENCES
1.  American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. (2004). Management of
hyperbilirubinemia in the newborn infant 35 or more weeks gestation. Pediatrics, 114(1), 297-316.
2.  Bhutani VK, Stark AR, Lazzeroni LC, et al. (2013). Pre-discharge screening for severe neonatal
hyperbilirubinemia identifies infants who need phototherapy. Journal of Pediatrics, 162(3), 477–482.
3.  Romero HM, Ringer C, Leu MG, et al. (2018). Neonatal jaundice: Improved quality and cost savings
after implementation of a standard pathway. Pediatrics, 141(3), doi: 10.1542
4.  Utidjian L., Monforto K., Rezet B., et al. (2016). Pathway for evaluation/treatment of neonates with































































■ Pre-intervention: October–December, 2017
■ Intervention: January, 2018
■ Post-intervention: February–November, 2018
























































































■ Pre-intervention: October–December, 2017
■ Intervention: January, 2018
■ Post-intervention: February–November, 2018
—Target 80%
